Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — drug options
12 open options
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
ITI-1284 · Placebo — 70 sites
- TRIALPHASE3NOT_YET_RECRUITING
A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease
Deep cervical lymphatic-venous anastomosis · Donepezil drug treatment
- TRIALPHASE2RECRUITING
DORA and LP in Alzheimer's Disease Biomarkers
Lemborexant 10 mg · Lemborexant 20mg · Placebo — 1 site
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALPHASE2RECRUITING
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
EX039 · Placebo — 1 site
- TRIALPHASE4RECRUITING
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Gabapentin Enacarbil · Placebo Oral Tablet — 1 site
- TRIALEARLY_PHASE1RECRUITING
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Psilocybin — 1 site
- TRIALNARECRUITING
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
F-18 AV 1451 · C-11 PiB — 1 site
- TRIALPHASE4ENROLLING_BY_INVITATION
MIBG in Aging and Neurologic Disorders
meta-iodobenzylguanidine (MIBG) (123I) · 123I-MIBG scintigraphy — 1 site
- TRIALPHASE2 / PHASE3NOT_YET_RECRUITING
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
Dronabinol Oral Solution · Placebo Control — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
ABBV-1758 · Placebo for ABBV-1758 · ABBV-1758 — 12 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.